Page last updated: 2024-09-03

mk 0663 and Cardiovascular Diseases

mk 0663 has been researched along with Cardiovascular Diseases in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (68.18)	29.6817
2010's	5 (22.73)	24.3611
2020's	2 (9.09)	2.80

Authors

Authors	Studies
Pedersen, L; Schmidt, M; Sørensen, HT	1
Chan, EWY; Chan, L; Lam, CLK; Mok, AHY; Wan, EYF; Wang, Y; Wong, ICK; Yu, EYT	1
Martín Arias, LH; Martín González, A; Sanz Fadrique, R; Vazquez, ES	1
Ariano, C; Baldi, C; Cantatrione, S; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Valente, L	1
Davydkin, IL; Zolotovskaya, IA	1
Baglie, S; Baller, EM; Franco, GC; Gevert, MV; Lupepsa, AC; Moro, MG; Sanchez, PK; Tostes, AF	1
Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C	1
Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT	1
Capell, HA; Duncan, MR	1
Choi, YS; Kim, JA; Kim, SH	1
Patrignani, P; Rodríguez, LA	1
Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME	1
Bergman, G; Curtis, SP; Ko, AT; Malmstrom, K; Mehta, A; Reginster, JY; Reicin, AS	1
Psaty, BM; Weiss, NS	1
Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B	1
Tabrizchi, R	1
FitzGerald, GA	1
Einecke, D	1
Krüger, K	1
Baraf, HS	1
Avorn, J	1
Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y	1

Reviews

3 review(s) available for mk 0663 and Cardiovascular Diseases

Article	Year
Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies. Journal of clinical pharmacology, 2019, Volume: 59, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Etoricoxib; Humans; Observational Studies as Topic; Risk Factors	2019
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva cardioangiologica, 2014, Volume: 62, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Naproxen; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2014
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Current pharmaceutical design, 2007, Volume: 13, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones	2007

Trials

5 trial(s) available for mk 0663 and Cardiovascular Diseases

Article	Year
[Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain]. Terapevticheskii arkhiv, 2015, Volume: 87, Issue:12 Topics: Acute Pain; Aged; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Humans; Male; Meloxicam; Middle Aged; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome	2015
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford, England), 2009, Volume: 48, Issue:4 Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergencies; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Odds Ratio; Osteoarthritis; Pyridines; Safety; Sample Size; Sulfones; Thrombosis	2009
Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Pyridines; Sulfones; Time Factors; Treatment Outcome	2007
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. The Journal of rheumatology, 2007, Volume: 34, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pyridines; Sulfones; Treatment Outcome; Withholding Treatment	2007
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Annals of the rheumatic diseases, 2008, Volume: 67, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pyridines; Sulfones; Treatment Outcome	2008

Other Studies

14 other study(ies) available for mk 0663 and Cardiovascular Diseases

Article	Year
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials. Drug safety, 2022, Volume: 45, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etodolac; Etoricoxib; Female; Heart Disease Risk Factors; Humans; Meloxicam; Risk Factors	2022
Comparative Risks of Nonsteroidal Anti-inflammatory Drugs on Cardiovascular Diseases: A Population-Based Cohort Study. Journal of clinical pharmacology, 2023, Volume: 63, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Etoricoxib; Humans; Retrospective Studies; Risk Factors	2023
Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy. Brazilian oral research, 2016, Nov-28, Volume: 30, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cyclooxygenase 2 Inhibitors; Etoricoxib; Gastric Mucosa; Ibuprofen; Kidney; Kidney Diseases; Male; Platelet Aggregation Inhibitors; Pyridines; Random Allocation; Rats, Wistar; Risk Factors; Stomach Diseases; Sulfones; Time Factors; Treatment Outcome	2016
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal of rheumatology, 2011, Volume: 38, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diclofenac; Etoricoxib; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Osteoarthritis; Peptide Fragments; Prospective Studies; Pyridines; Retrospective Studies; Risk Factors; Sulfones; Thrombosis; Treatment Outcome	2011
Etoricoxib in the treatment of chronic pain. International journal of clinical practice, 2003, Volume: 57, Issue:4 Topics: Adult; Aged; Arthritis; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Gastrointestinal Diseases; Humans; Low Back Pain; Middle Aged; Pain; Pyridines; Randomized Controlled Trials as Topic; Sulfones	2003
Adverse effects of etoricoxib: other considerations. Mayo Clinic proceedings, 2005, Volume: 80, Issue:9 Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoricoxib; Gastrointestinal Diseases; Humans; Osteoarthritis; Pyridines; Sulfones	2005
The ever growing story of cyclo-oxygenase inhibition. Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Humans; Pyridines; Randomized Controlled Trials as Topic; Sulfones	2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones	2006
NSAID trials and the choice of comparators--questions of public health importance. The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials, Phase IV as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Drug Industry; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Pyridines; Sulfones; United States; United States Food and Drug Administration	2007
Coxibs: can this class of drugs survive? Vascular health and risk management, 2005, Volume: 1, Issue:1 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2005
COX-2 in play at the AHA and the FDA. Trends in pharmacological sciences, 2007, Volume: 28, Issue:7 Topics: American Heart Association; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; Etoricoxib; Humans; Pyridines; Sulfones; United States; United States Food and Drug Administration	2007
[Coronary risks with NSAID and coxibs. The end of hysteria]. MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause of Death; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Peptic Ulcer; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis	2006
[3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]]. MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Peptic Ulcer; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones	2006
Keeping science on top in drug evaluation. The New England journal of medicine, 2007, Aug-16, Volume: 357, Issue:7 Topics: Advisory Committees; Cardiovascular Diseases; Conflict of Interest; Cyclooxygenase Inhibitors; Dexfenfluramine; Drug Approval; Drug Evaluation; Drug Industry; Etoricoxib; Humans; Hypoglycemic Agents; Lactones; Pyridines; Risk; Rosiglitazone; Sulfones; Thiazolidinediones; United States; United States Food and Drug Administration	2007